| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8273885 | Journal of the Neurological Sciences | 2016 | 6 Pages |
Abstract
CDAS appears to have sufficient face-validity as a grading system to assess disease activity in relation to treatment status. The use of CDAS appears to allow benchmarking of patients with CIDP that may be useful in subject selection for clinical trials and also to highlight differences in practice.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Hana Albulaihe, Majed Alabdali, Abdulla Alsulaiman, Alon Abraham, Ari Breiner, Carolina Barnett, Hans D. Katzberg, Leif E. Lovblom, Bruce A. Perkins, Vera Bril,